T1ρ-MRI预测成人型弥漫性胶质瘤分子亚型与WHO分级
该前瞻性研究纳入62例成人型弥漫性胶质瘤患者,术前行形态学MRI、DWI及不同自旋锁定频率(100/200/500 Hz)的T1ρ-MRI,评估T1ρ对WHO分级、IDH突变和MGMT启动子甲基化的预测价值。结果显示T1ρ(500 Hz)是IDH突变的独立预测因子,AUC达0.873,但加入mMRI+ADC模型后对WHO分级和IDH突变的AUC提升无统计学意义。
要点
- T1ρ(500 Hz)是IDH突变状态的独立预测因子,诊断效能最高。
- 高级别胶质瘤和IDH野生型肿瘤的ADC及T1ρ值显著低于对照组。
- T1ρ加入mMRI+ADC模型后AUC数值略升但无统计学显著增益。
核心结论
- T1ρ-MRI在预测胶质瘤WHO分级和IDH突变方面具有临床价值。
- T1ρ在500 Hz时诊断效能优于ADC及更低自旋锁定频率。
- 联合mMRI和ADC可提高诊断准确性,但加入T1ρ-MRI未带来显著额外获益。
研究设计与样本
- 前瞻性研究,共纳入62例成人型弥漫性胶质瘤患者。
- 术前成像包括形态学MRI、弥散加权成像和T1ρ-MRI,自旋锁定频率设为100 Hz、200 Hz和500 Hz。
- 采用t检验和卡方检验进行组间比较,逻辑回归筛选独立特征,ROC曲线评估诊断效能。
主要发现
- 高级别胶质瘤和IDH野生型肿瘤患者的ADC和T1ρ值显著低于对照组(p < 0.05)。
- T1ρ(FSL = 500 Hz)是IDH突变状态的独立预测因子(p < 0.05),预测IDH突变的AUC为0.873(95% CI: 0.782-0.951; p < 0.001)。
- mMRI与ADC联合优于单一参数;mMRI+ADC+T1ρ模型对WHO分级和IDH突变的AUC分别为0.948和0.920,高于mMRI+ADC模型的0.933和0.866,但差异无统计学意义(p = 0.205; p = 0.150)。
临床怎么用
- T1ρ-MRI(尤其500 Hz)可作为无创预测IDH突变和WHO分级的辅助工具。
- 在mMRI+ADC基础上加做T1ρ-MRI对诊断准确性的提升有限,需权衡临床必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to investigate the utility of quantitative T1ρ magnetic resonance imaging (T1ρ-MRI) in predicting the WHO grade, isocitrate dehydrogenase (IDH) mutation, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in adult-type diffuse gliomas, and compare their performance across different spin-lock frequencies (FSLs). METHODS: A total of 62 patients were prospectively recruited and underwent preoperative imaging, including morphological MRI (mMRI), diffusion-weighted imaging (DWI) and T1ρ-MRI. T1ρ was performed with FSLs set at 100 Hz, 200 Hz, and 500 Hz. Group comparisons by IDH mutation, WHO grade, and MGMT status were performed using t-tests and chi-square tests. Logistic regression analysis was employed to identify features independently. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of the predictive models. RESULTS: The apparent diffusion coefficient (ADC) and T1ρ values were significantly lower in patients with high-grade gliomas (HGGs) and IDH wildtype tumors compared to the control group (p < 0.05). T1ρ (FSL = 500 Hz) was identified as an independent predictor of IDH mutation status (p < 0.05) and demonstrated the highest diagnostic performance for predicting IDH mutation (AUC = 0.873; 95% CI: 0.782-0.951; p < 0.001). The combination of mMRI and ADC outperformed individual parameters. When T1ρ was added to the mMRI + ADC model, the resulting mMRI + ADC + T1ρ model achieved higher AUC values for both WHO grade and IDH mutation than the mMRI + ADC model alone, but these differences were not statistically significant (0.948 vs. 0.933, p = 0.205; 0.920 vs. 0.866, p = 0.150, respectively). CONCLUSION: T1ρ-MRI demonstrates promising clinical value in predicting WHO grade and IDH mutation in gliomas. Notably, T1ρ at 500 Hz showed superior diagnostic performance compared to ADC and lower FSL settings. Integrating mMRI and ADC further enhances diagnostic accuracy, whereas adding T1ρ-MRI provides no significant additional benefit despite a slight numerical gain.
引用
- Dai X, He S, Qi Y, et al. Predictive markers for molecular subtypes and WHO grade: T1ρ-MRI in adult-type diffuse gliomas. J Neurooncol. 2025. PMID: 41085784. doi:10.1007/s11060-025-05271-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。